Human testing of the malaria shot should get underway by the end of 2022, according to the German biotech, which says it is working with the World Health Organization (WHO), European Commission and other organisations on the malaria project.
There is a malaria vaccine on the market – GlaxoSmithKline’s Mosquirix – but this is only around 39% effective so has not been backed by the WHO. Given the massive health problem posed by malaria It is nevertheless being used in programmes to protect children in areas where the parasite is particularly problematic, such as sub-Saharan Africa.
